BioSpace News Archive

Scholar Rock today announced it will host an Investor Day on Wednesday, May 22, 2024 beginning at 8:30 a.m. ET in New York City.

Allurion Technologies, Inc. today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.

Enveric Biosciences today announced that it has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs (“NPP”) to Vancouver, BC-based MindBio Therapeutics.

Veru Inc. announced that Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer, will be a Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week, taking place May 21-23, 2024, in Tel Aviv, Israel.

RenovoRx, Inc. announced that Shaun Bagai, Chief Executive Officer, will participate in a fireside chat at Alliance Global Partners Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P.

Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, announced two-year results from the BIOADAPTOR Randomized Controlled Trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute OnyxTM Drug-Eluting Stent from 34 centers in Japan, Europe, and New Zealand.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical

Nurix Therapeutics, Inc. announced an upcoming oral presentation highlighting new clinical data from Nurix’s orally available, selective BTK degrader, NX-5948, at the European Hematology Association Congress which is being held from June 13 - 16, 2024, in Madrid, Spain, and virtually.

Editas Medicine, Inc. announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel have been accepted for presentation at the European Hematology Association Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream.

Kymera Therapeutics, Inc. announced that new Phase 1 data for KT-333, a first-in-class degrader of STAT3, highlighting safety, pharmacokinetics, pharmacodynamics and clinical responses will be presented at the European Hematology Association Annual Meeting, taking place from June 13-16, 2024, in Madrid, Spain.